VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IMS 2022 | Anti-BCMA lipid-based nanoparticle therapeutic strategy for patients with multiple myeloma

Zahraa Al-Ahmady, BSc, MSc, PhD, Nottingham Trent University, Nottingham, UK, discusses the feasibility and advantages of a novel anti-BCMA lipid-based nanoparticle therapeutic strategy designed to improve the tolerance and availability of BCMA-directed therapies for patients with multiple myeloma. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter